title: Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.
abstract: Preexisting renal impairment is an all-encompassing risk factor for radiocontrast-associated nephrotoxicity. Renal impairment appears to be associated with the inadequate production of renal prostaglandins at the critical time of radiocontrast administration and for a variable time period afterward. We prospectively studied 130 patients with chronic renal insufficiency (serum creatinine > or =1.5 mg/dL) who were undergoing radiocontrast administration. Using a double-blind, randomized, prospective technique, patients were assigned to either placebo or one of three prostaglandin E1 (PGE1) treatment groups (10, 20, or 40 ng/kg/min). Infusion was started 60 +/- 30 minutes before the administration of radiocontrast and was continued for a total of 6 hours. In the placebo group, radiocontrast administration resulted in a mean increase (+/- SD) in serum creatinine of 0.72 +/- 1.15 mg/dL at 48 hours. This increase was less in each of the PGE1 treatment groups after 48 hours, with a significant difference between placebo and the 20 ng/kg/min PGE1 group (P = 0.01). Using baseline adjusted means, analysis of covariance with baseline serum creatinine as the covariable demonstrated significant differences between the placebo and 20 ng/kg/min PGE1 group (P = 0.03) and between the placebo and 10 ng/kg/min PGE1 group P = 0.047). In a subgroup analysis of the diabetic patients, the increase in serum creatinine was less pronounced in the three PGE1 groups versus the placebo group, and the 20 ng/kg/min PGE1 group had the most favorable outcome. The parenteral administration of PGE1 immediately before radiocontrast exposure and continued for a period of 5 to 5.5 hours significantly reduced the elevation of serum creatinine poststudy. The most effective of the three PGE1 dosing regimens was 20 ng/kg/min.
authors.affiliation: Duke University Medical Center, Durham, NC 27710, USA. sketc002@mc.duke.edu
authors.forename: M H
authors.initials: MH
authors.lastname: Sketch
authors.forename: A
authors.initials: A
authors.lastname: Whelton
authors.forename: E
authors.initials: E
authors.lastname: Schollmayer
authors.forename: J A
authors.initials: JA
authors.lastname: Koch
authors.forename: P J
authors.initials: PJ
authors.lastname: Bernink
authors.forename: F
authors.initials: F
authors.lastname: Woltering
authors.forename: J
authors.initials: J
authors.lastname: Brinker
mesh_terms: D000368:Aged; D000527:Alprostadil / Q000627:therapeutic use*; D000704:Analysis of Variance; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D003287:Contrast Media; D003404:Creatinine; D000527:Alprostadil